Isolation of circulating tumor cells in a preclinical model of osteosarcoma: Effect of chemotherapy
- PMID: 30123735
- PMCID: PMC6092555
- DOI: 10.1016/j.jbo.2018.07.002
Isolation of circulating tumor cells in a preclinical model of osteosarcoma: Effect of chemotherapy
Abstract
Osteosarcoma is a rare primary bone tumor, which mainly affects children and adolescents and has a poor prognosis, especially for patients with metastatic disease. A poor therapeutic response to the conventional chemotherapy is observed with the development of lung metastases, highlighting the need for improving the current regimens and the identification of early markers of the recurrent and metastatic disease. Circulating Tumour Cells (CTCs) play a key role in the metastatic process and could be powerful biomarkers of the progressive disease. The present study aimed to isolate CTCs by using a pre-clinical model of human osteosarcoma and to monitor their kinetic of release and their modulation by ifosfamide. CTCs were detectable into the bloodstream before any palpable primary tumors. Ifosfamide increased CTCs count and in contrast decreased the number of lung tumor nodules. On established tumors, ifosfamide slowed down the tumour growth and did not modulate CTC count that could be explained by a release of cancer cells from the primary tumour with reduced properties for inducing lung metastases. This report highlights the biological interest of CTCs in osteosarcoma.
Keywords: Biomarker; Circulating tumor cells; Metastatic process; Osteosarcoma; Recurrent disease.
Figures





Similar articles
-
Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide.Oncol Rep. 2000 Mar-Apr;7(2):339-46. doi: 10.3892/or.7.2.339. Oncol Rep. 2000. PMID: 10671683 Clinical Trial.
-
The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.Cancer Commun (Lond). 2019 Jan 3;39(1):1. doi: 10.1186/s40880-018-0346-4. Cancer Commun (Lond). 2019. PMID: 30606259 Free PMC article. Clinical Trial.
-
Prognostic and clinicopathological significance of circulating tumor cells in osteosarcoma.J Bone Oncol. 2019 Apr 3;16:100236. doi: 10.1016/j.jbo.2019.100236. eCollection 2019 Jun. J Bone Oncol. 2019. PMID: 31024791 Free PMC article.
-
Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer.Lung Cancer. 2012 Apr;76(1):19-25. doi: 10.1016/j.lungcan.2011.10.018. Epub 2011 Dec 29. Lung Cancer. 2012. PMID: 22209049 Review.
-
Circulating tumor cells in precision oncology: clinical applications in liquid biopsy and 3D organoid model.Cancer Cell Int. 2019 Dec 18;19:341. doi: 10.1186/s12935-019-1067-8. eCollection 2019. Cancer Cell Int. 2019. PMID: 31866766 Free PMC article. Review.
Cited by
-
Liquid biopsies in primary and secondary bone cancers.Cancer Drug Resist. 2022 Jun 21;5(3):541-559. doi: 10.20517/cdr.2022.17. eCollection 2022. Cancer Drug Resist. 2022. PMID: 36176757 Free PMC article. Review.
-
Novel molecular insights and new therapeutic strategies in osteosarcoma.Cancer Cell Int. 2018 Oct 16;18:158. doi: 10.1186/s12935-018-0654-4. eCollection 2018. Cancer Cell Int. 2018. PMID: 30349420 Free PMC article. Review.
-
Circulating Tumor Cells as a Tool for Assessing Tumor Heterogeneity.Theranostics. 2019 Jun 19;9(16):4580-4594. doi: 10.7150/thno.34337. eCollection 2019. Theranostics. 2019. PMID: 31367241 Free PMC article. Review.
-
Biopsy Techniques for Musculoskeletal Tumors: Basic Principles and Specialized Techniques.Curr Oncol. 2024 Feb 5;31(2):900-917. doi: 10.3390/curroncol31020067. Curr Oncol. 2024. PMID: 38392061 Free PMC article. Review.
-
An overview of resistance to chemotherapy in osteosarcoma and future perspectives.Cancer Drug Resist. 2022 Jun 23;5(3):762-793. doi: 10.20517/cdr.2022.18. eCollection 2022. Cancer Drug Resist. 2022. PMID: 36176756 Free PMC article. Review.
References
-
- Mohseny A.B., Szuhai K., Romeo S., Buddingh A.P., Briaire-de Bruijn I., de Jong D., van Pel M., Cleton-Jansen A.M., Hogendoorn P.C. Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J. Pathol. 2009;219:294–305. - PubMed
-
- Mutsaers A.J., Walkley C.R. Cells of origin in osteosarcoma: mesenchymal stem cells or osteoblast committed cells? Bone. 2014;62:56–63. - PubMed
-
- Heymann M.F., Brown H.K., Heymann D. Drugs in early clinical development for the treatment of osteosarcoma. Expert Opin. Investig. Drugs. 2016;25:1265–1280. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources